Patents Assigned to Profectus Biosciences, Inc.
  • Recombinant isfahan viral vectors
    Patent number: 9932564
    Abstract: Certain embodiments are directed to recombinant vesiculovirus encoding a heterologous polynucleotide and methods of using the same.
    Type: Grant
    Filed: February 27, 2015
    Date of Patent: April 3, 2018
    Assignees: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM, PROFECTUS BIOSCIENCES, INC.
    Inventors: Demetrius Matassov, Rodion V. Gorchakov, Stefan Hamm, Rebecca Nowak, Robert L. Seymour, John H. Eldridge, Robert B. Tesh, David K. Clarke, Theresa E. Latham, Scott Weaver, Farooq Nasar
  • Inhibitors of NF-?B
    Patent number: 8629164
    Abstract: The invention relates to compounds of formulae (1) and (2): and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries.
    Type: Grant
    Filed: March 25, 2010
    Date of Patent: January 14, 2014
    Assignee: Profectus Biosciences, Inc.
    Inventors: Jie Zhang, Drago Robert Sliskovic, Charles E. Ducker
  • Oxabicyclo[4.1.0]Hept-B-en-S-yl Carbamoyl Derivatives Inhibiting The Nuclear Factor-Kappa (B) - (NF-KB)
    Publication number: 20120088827
    Abstract: The invention relates to compounds of formula (I), formula (II), formula (III) and formula (IV), and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries.
    Type: Application
    Filed: June 16, 2010
    Publication date: April 12, 2012
    Applicant: Profectus Biosciences, Inc.
    Inventors: Jie Zhang, Drago Robert Sliskovic, Charles E. Ducker
  • Benzamide and Napthamide Derivatives Inhibiting Nuclear Factor-Kappa (B) - (NK-kB)
    Publication number: 20120046357
    Abstract: The invention relates to compounds of formula (1) and formula (2), and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries, wherein R1 is defined herein.
    Type: Application
    Filed: April 29, 2010
    Publication date: February 23, 2012
    Applicant: Profectus Biosciences, Inc.
    Inventors: Jie Zhang, Drago Robert Sliskovic, Charles E. Ducker
  • Inhibitors of NF-KB
    Publication number: 20120015952
    Abstract: The invention relates to compounds of formulae (1) and (2): and pharmaceutically acceptable salts thereof for the treatment of cancer, inflammation, auto-immune diseases, diabetes and diabetic complications, infection, cardiovascular disease and ischemia-reperfusion injuries.
    Type: Application
    Filed: March 25, 2010
    Publication date: January 19, 2012
    Applicant: Profectus Biosciences, Inc.
    Inventors: Jie Zhang, Drago Robert Sliskovic, Charles E. Ducker